Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285400 | 0.99 | TDP1 (0.47) | TDP1POLBAPEX1HTTTSHR | |
| SCHEMBL295983 | 0.95 | TDP1 (0.45) | TDP1POLBAPEX1HTTTSHR | |
| SCHEMBL285289 | 0.89 | POLB (0.41) | TDP1POLBAPEX1HTTTSHR | |
| SCHEMBL285640 | 0.82 | TSHR (0.49) | TDP1TSHRPTGS2CHRM2CHRM4 | |
| SCHEMBL285406 | 0.81 | THRB (0.47) | TDP1TSHRPTGS2CHRM2CHRM4 | |
| SCHEMBL8028295 | 0.80 | TDP1 (0.55) | TDP1POLBAPEX1HTTTSHR | |
| SCHEMBL285646 | 0.80 | TDP1 (0.55) | TDP1POLBAPEX1HTTTSHR | |
| SCHEMBL285399 | 0.79 | KIF11 (0.44) | TDP1POLBAPEX1HTTTSHR | |
| SCHEMBL8028273 | 0.78 | TDP1 (0.52) | TDP1POLBAPEX1HTTTSHR | |
| SCHEMBL285514 | 0.77 | KIF11 (0.49) | TDP1POLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729203-B2 | Polymer composition | CONTAMAC LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2427509-A1 | POLYMER COMPOSITION | Contamac Limited (GB) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053313-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010128266-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053313-A1 | POLYMER COMPOSITION | UACA, CRYAA, CRYZ | TDP1 3344/4885POLB 1398/4885APEX1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.